Ceramide 1-Phosphate Protects Endothelial Colony–Forming Cells From Apoptosis and Increases Vasculogenesis In Vitro and In Vivo by Mena, Hebe Agustina et al.
HAL Id: hal-02326078
https://hal.archives-ouvertes.fr/hal-02326078
Submitted on 25 Oct 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Ceramide 1-Phosphate Protects Endothelial
Colony–Forming Cells From Apoptosis and Increases
Vasculogenesis In Vitro and In Vivo
Hebe Agustina Mena, Paula Romina Zubiry, Blandine Dizier, Virginie
Mignon, Fernanda Parborell, Mirta Schattner, Catherine Boisson-Vidal,
Soledad Negrotto
To cite this version:
Hebe Agustina Mena, Paula Romina Zubiry, Blandine Dizier, Virginie Mignon, Fernanda Parborell, et
al.. Ceramide 1-Phosphate Protects Endothelial Colony–Forming Cells From Apoptosis and Increases
Vasculogenesis In Vitro and In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, American
Heart Association, 2019, 39 (10), ￿10.1161/ATVBAHA.119.312766￿. ￿hal-02326078￿
Arteriosclerosis, Thrombosis, and Vascular Biology
Arterioscler Thromb Vasc Biol is available at www.ahajournals.org/journal/atvb
Arterioscler Thromb Vasc Biol. 2019;39:00–00. DOI: 10.1161/ATVBAHA.119.312766 October 2019  1
 
Correspondence to: Soledad Negrotto, PhD, Experimental Thrombosis Laboratory, Institute of Experimental Medicine, National Academy of Medicine–CONICET, 
Pacheco de Melo 3081, Buenos Aires, Argentina. Email solenegrotto@hematologia.anm.edu.ar or solenegrotto@hotmail.com
The online-only Data Supplement is available with this article at https://www.ahajournals.org/doi/suppl/10.1161/ATVBAHA.119.312766.
For Sources of Funding and Disclosures, see page xxx.
© 2019 American Heart Association, Inc.
ORIGINAL RESEARCH
Ceramide 1-Phosphate Protects Endothelial 
Colony–Forming Cells From Apoptosis and 
Increases Vasculogenesis In Vitro and In Vivo
Hebe Agustina Mena, Paula Romina Zubiry, Blandine Dizier, Virginie Mignon, Fernanda Parborell, Mirta Schattner,  
Catherine Boisson-Vidal, Soledad Negrotto
OBJECTIVE: Ceramide 1-phosphate (C1P) is a bioactive sphingolipid highly augmented in damaged tissues. Because of its 
abilities to stimulate migration of murine bone marrow–derived progenitor cells, it has been suggested that C1P might be 
involved in tissue regeneration. In the present study, we aimed to investigate whether C1P regulates survival and angiogenic 
activity of human progenitor cells with great therapeutic potential in regenerative medicine such as endothelial colony– 
forming cells (ECFCs).
APPROACH AND RESULTS: C1P protected ECFC from TNFα (tumor necrosis factor-α)-induced and monosodium urate crystal–
induced death and acted as a potent chemoattractant factor through the activation of ERK1/2 (extracellular signal-regulated 
kinases 1 and 2) and AKT pathways. C1P treatment enhanced ECFC adhesion to collagen type I, an effect that was 
prevented by β1 integrin blockade, and to mature endothelial cells, which was mediated by the E-selectin/CD44 axis. ECFC 
proliferation and cord-like structure formation were also increased by C1P, as well as vascularization of gel plug implants 
loaded or not with ECFC. In a murine model of hindlimb ischemia, local administration of C1P alone promoted blood perfusion 
and reduced necrosis in the ischemic muscle. Additionally, the beneficial effects of ECFC infusion after ischemia were 
amplified by C1P pretreatment, resulting in a further and significant enhancement of leg reperfusion and muscle repair.
CONCLUSIONS: Our findings suggest that C1P may have therapeutic relevance in ischemic disorders, improving tissue repair by 
itself, or priming ECFC angiogenic responses such as chemotaxis, adhesion, proliferation, and tubule formation, which result 
in a better outcome of ECFC-based therapy (Visual Overview).
Key Words: cell transplantation ◼ endothelial progenitor cells ◼ humans ◼ ischemia ◼ regeneration
Building new vascular networks to reestablish blood perfusion is one of the therapeutic goals to treat ischemic vascular diseases such as critical limb 
ischemia, stroke, and myocardial infarction. Restitution 
of blood flow to the injured site may require angiogenic 
sprouting of endothelial cells from nearby intact blood 
vessels, as well as the recruitment of endothelial pro-
genitor cells from the bone marrow to initiate vasculo-
genesis.1 Several progenitor cell populations with a role 
in angiogenesis have been isolated; however, the endo-
thelial colony–forming cells (ECFCs) truly represent an 
endothelial cell type with potent intrinsic clonal prolifera-
tive potential and capacity to contribute to de novo blood 
vessel formation in vivo.2,3 Moreover, ECFCs are the most 
potent vascular reparative cell type among endothelial 
progenitor cell candidates,4 and its key role on postisch-
emia tissue vascularization has been shown in different 
models in athymic nude mice.5,6
Sphingolipids are membrane lipids that have been con-
sidered for many years as simple structural cell compo-
nents. However, in the last decades, increasing evidence 
has shown that sphingolipids are powerful bioactive 
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molecules, which regulate vital cellular functions such as 
the cell cycle and survival, as well as the inflammatory 
and immune responses.7 Ceramide—the fundamental 
structural unit of all sphingolipids—can be deacylated to 
sphingosine, which is then phosphorylated by sphingo-
sine kinases (SPHK1 or SPHK2) to yield sphingosine 
1-phosphate. Also, ceramide 1-phosphate (C1P) can be 
generated by phosphorylation of ceramide (N-acyl sphin-
gosine) by CERK (ceramide kinase).8 Both sphingosine 
1-phosphate and C1P production are increased under 
inflammatory conditions. While sphingosine 1-phos-
phate can be secreted by normal activated cells, C1P 
is released as a consequence of the loss of membrane 
permeability or cell rupture.9 Thus, C1P is considered 
a damage-associated molecular pattern as it rapidly 
and exponentially increases its levels in sites of tissue 
injury.10 C1P exerted antiapoptotic effects in several cell 
types,11–14 and it is a powerful chemoattractant not only 
for macrophages15 but also for different progenitor/stem 
cells, including murine bone marrow–derived endothe-
lial progenitor cells.9,10 Moreover, C1P stimulates human 
umbilical vein endothelial cell (HUVEC)–mediated cap-
illary-like tubule formation in vitro and matrigel implant 
vascularization.10 Interestingly, it has been reported that 
dermal microendothelial cells from CERK-deficient mice 
show profound defects in in vitro angiogenesis assays.16
Based on this background, in the present study, we 
aimed to investigate whether C1P regulates survival and 
vasculogenic activity of human progenitor cells with a 
high potential in regenerative medicine such as ECFC. 
We found that C1P increases ECFC survival and angio-
genic responses including chemotaxis, adhesion, prolif-
eration, and tubule formation. Additionally, in an in vivo 
model of hindlimb ischemia, C1P improved tissue regen-
eration by itself and acted as a primer of ECFC regen-
erative properties.
MATERIALS AND METHODS
The authors declare that all supporting data are available within 
the article and its online-only Data Supplement.
Lipid Preparation and Endothelial Cell Culture
C8-C1P d18:1/8:0 (C8-C1P) and C16-C1P d18:1/16:0 
(C16-C1P; C8 cat No. 860532P, C16 cat No. 860533P; 
Avanti Polar Lipids, Inc, Alabaster, AL) were prepared in ultra-
pure water by sonication on ice using a probe sonicator until 
a clear dispersion was observed. Sonicated ultrapure water 
served as the appropriate vehicle (untreated control).
This study conforms to the principles outlined in the 
Declaration of Helsinki and received prior approval by the 
Institutional Ethics Committee (National Academy of Medicine, 
Argentina). Umbilical cord and cord blood were collected after 
normal full-term deliveries with the written informed consent 
of the mother. ECFCs and HUVECs were purified from human 
umbilical cord blood and umbilical cord, respectively. Both cells 
were cultured and characterized as described previously.17,18 
Only HUVECs from the first 4 passages and ECFCs during the 
first 40 days of culture were used for experiments.
Experimental Design
Endothelial cells in endothelial basal medium 2 (Lonza, 
Walkersville, MD) with 2% fetal bovine serum or endothe-
lial growth medium 2 (Lonza) were treated with 0.1, 1, or 10 
µmol/L C8-C1P, C16-C1P, or vehicle. Pharmacological inhibi-
tors of ERK1/2 (extracellular signal-regulated kinases 1 and 2; 
U-0126, cat No. BML-EI-282; Enzo Life Sciences International, 
Inc, San Diego, CA) or AKT (LY-294002, cat No. BML-ST420; 
Enzo Life Sciences International, Inc) were added to ECFC cul-
tures 30 minutes before C1P.
Nonstandard Abbreviations and Acronyms
bFGF basic fibroblast growth factor
C1P ceramide 1-phosphate
CERK ceramide kinase
ECFC endothelial colony–forming cell
ERK1/2  extracellular signal-regulated kinases 1 
and 2
HUVEC human umbilical vein endothelial cell
ICAM-1 intercellular adhesion molecule 1
IL interleukin
MSU monosodium urate crystals
PI3K phosphatidylinositol 3-kinase pathway
SDF-1 stromal cell-derived factor 1
TGFβ1 transforming growth factor-β1
TNFα tumor necrosis factor-α
VEGF vascular endothelial growth factor
VEGFR2  vascular endothelial growth factor recep-
tor 2
Highlights
• Ceramide 1-phosphate supported vasculogenesis 
by increasing endothelial colony forming cell (ECFC) 
survival and acting as a potent ECFC chemoattrac-
tant factor alone or in synergy with SDF-1 (stromal 
cell-derived factor 1).
• Ceramide 1-phosphate enhanced ECFC angiogenic 
properties including adhesion, proliferation, and 
tubule formation in vitro and in vivo.
• In a murine model of hindlimb ischemia, ceramide 
1-phosphate induces postischemia revasculariza-
tion and tissue repair by itself and further improved 
ECFC regenerative potential.
• Ceramide 1-phosphate might be considered a new 
therapeutic tool in ischemic disorders itself or as an 
improver of the outcome of ECFC-based therapy.
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Measurement of Cell Viability
ECFCs cultured in endothelial basal medium 2/2% fetal bovine 
serum were treated with the different stimuli, and cell viability 
was determined after 24 hours by nuclear morphology analy-
sis.18 Briefly, adherent cells were harvested using 0.05% trypsin 
and pooled with spontaneously detached cells. Cells were then 
stained with 100 µg/mL ethidium bromide and acridine orange 
(Sigma, St. Louis, MA), mounted on slides and immediately ana-
lyzed by fluorescence microscopy. At least 300 cells per treat-
ment were counted.
A similar procedure was used to measure caspase-3 activa-
tion by flow cytometry. Briefly, cells were fixed, permeabilized, 
and then stained with fluorescein isothiocyanate-conjugated 
monoclonal antibody against the active fragment of cas-
pase-3 (cat No. 51-68654X; BD Biosciences, Bedford, MA) 
for 30 minutes. Acquisition and analysis were achieved by flow 
cytometry (FACScalibur; BD Biosciences, San Jose, CA) using 
FlowJo (Flexera, Itasca, IL).
Measurement of Angiogenic Responses
Chemotaxis driven by C1P or SDF-1 (stromal-derived factor 
1) was examined using transwells with 8.0-µm pore polycar-
bonate membrane inserts. The number of migrated cells was 
determined by counting under a high-power microscope.
For cell adhesion assays, ECFCs were stained with carboxy-
fluorescein succinimidyl ester and adhesion onto recombinant 
bovine fibronectin, rat tail collagen type I or HUVEC untreated 
or activated with TNFα (tumor necrosis factor-α) was deter-
mined after 1 hour. Images were obtained with phase-contrast 
confocal fluorescence microscopy using a FV-1000 micro-
scope (Olympus), and the number of adherent cells was deter-
mined by cell count in 5 random fields.
ECFC proliferation was determined by cell counting in a 
Neubauer chamber or by carboxyfluorescein succinimidyl ester 
staining and flow cytometry.
Tube formation on reduced growth factor basement mem-
brane matrix (cat No. A1413202, Geltrex; Gibco, Grand Island, 
NY) was examined by phase-contrast microscopy, and the total 
number of branch points was quantified by analyzing images of 
the entire surface. Image analysis was performed with ImageJ.
Intracellular pathway phosphorylation levels were measured 
by flow cytometry using specific antibodies against phospho 
ERK1/2 (Tyr 202/Tyr 204), AKT (Ser 473), P38 (Tyr 182), and 
P65 (Ser 311) and confirmed by Western blot using primary 
antibody anti-phospho ERK1/2 (Tyr 204) and anti-phospho 
AKT (Ser 473) followed by an HRP-conjugated secondary 
antibody.
Animal Experiments
All experiments involving animals were performed according to 
protocols approved by the Animal Care and Use Committee 
of the Paris Descartes University Institutional Committee 
on Animal Care and Use (APAFIS No. 7443-201 61 020 
1540639 v2). Animal care was conformed to French guide-
lines (Services Vétérinaires de la Santé et de la Production 
Animale, Paris, France). Animals were housed in a tempera-
ture- and light-controlled (12/12-hour light/dark cycle) facility 
with free access to water and M20 standard diet (Special Diets 
Services, Witham, England).
In adherence to the guidelines as described in the ATVB 
Council Statement (ATVB. 2018;38:292–303), we reported 
that only 8-week-old nonconsanguine male NMRI-Foxn1nu/
Foxnu were used to exclude any effects of female hormones, 
such as estrogen, in this study. After treatment, mice were 
housed in clean cages (Tecniplast 1284 L Eurostandard type 
II L polysulfone, 5 mice/cage) in a well-ventilated room and 
allowed unrestricted access to feeds and water.
For Geltrex plug assay, mice were injected subcutaneously 
with 200 µL of Geltrex alone, or with C8-C1P (1 µmol/L), ECFC 
alone (1.5×106), or ECFC and C8-C1P. Mice were euthanized 
on day 10, and the Geltrex plugs were photographed, and the 
hemoglobin concentration was measured in the supernatants 
with Drabkin reagent (Sigma).19
Murine model of hindlimb ischemia, mice underwent sur-
gery to induce unilateral hindlimb ischemia by ligation of the 
right femoral artery as described previously.17 ECFCs (1×105) 
untreated or treated with C8-C1P (1 µmol/L) were adminis-
tered 5 hours after occlusion in the retro-orbital plexus. Saline 
solution was used as vehicle. Some animals received intramus-
cular injection of C8-C1P (1 µmol/L). The ischemic/normal 
limb blood flow ratio was determined on day 14 using the laser 
Doppler perfusion imaging system PeriScan Pim3 (Perimed, 
Crappone, France). Gastrocnemius muscles from both 
hindlimbs were fixed in 4% formol and embedded in paraffin 
and stained with hematoxylin and eosin and then digitized for 
quantified necrotic, ischemic, or preserved area in each muscle 
and reported as a percentage of the entire surface area of the 
section. Vessel density was evaluated in sections stained with 
primary rat anti-mouse CD31 monoclonal antibody (cat No. 
550274; BD Biosciences) and high-definition microangiogra-
phy Erase (Trophy system) and was expressed as the percent-
age of pixels per image in the quantification area occupied by 
vessels (CD31+ area).
Statistical Analysis
Results are expressed as means±SEM. P<0.05 was consid-
ered statistically significant. The Shapiro-Wilk test was used to 
define state normality and equal variance. In case of sample 
normality and equal variances, parametric tests such as 1- and 
2-way ANOVA followed by Fisher or Student t test were used. 
If normality assumption failed, nonparametric tests such as 
Kruskal-Wallis followed by Dunn or Mann-Whitney U test were 
performed. All the tests were used according to the experimen-
tal design and analyzed using the GraphPad software (PRISM, 
version 8.0; San Diego, CA).
RESULTS
C1P Promotes ECFC Survival and Migration
Chemoattraction and cytoprotection are two of the best-
known properties of the C1P described in many cell 
types, except in human endothelial precursors. In the 
present study, we first aimed to analyze the C1P effect 
on ECFC survival. ECFCs were treated with 2 different 
C1P analogs, a synthetic short-chain C8-C1P and the 
natural long-chain C16-C1P, and cell death was mea-
sured after 24 hours by nuclear morphology analysis. 
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We found that while C16-C1P failed to induce ECFC 
death in all concentrations tested (0.1–10 µmol/L), 
C8-C1P had a significant cytotoxic effect at 10 µmol/L 
(Figure 1A). C1P induced ECFC apoptosis since nuclear 
morphology was compatible with apoptosis (nuclear 
pyknosis), and caspase-3 was activated by 10 µmol/L 
C8-C1P (C=2.0±0.5, C1P=18.8±4.8% of positive cells 
by flow cytometry; P<0.05, n=4).
Numerous studies support the antiapoptotic effect 
of C1P in different cell types including macrophages, 
keratinocytes, cochlear hair cells, and retina photorecep-
tors.11–14 To mimic the different stress signals present at 
the inflammatory and ischemic microenvironment, we 
induced apoptosis and necrosis with 2 molecules highly 
elevated in these contexts like TNFα and monosodium 
urate crystal, respectively.5 C1P analogs were used at 
the maximum noncytotoxic concentration. Both C8- 
and C16-C1P significantly reduced monosodium urate 
crystal–induced necrosis by 40% approximately and fully 
suppressed TNFα apoptotic effect (Figure 1B).
Chemoattractant properties of C1P were first reported 
in macrophages15 and more recently in different murine 
bone marrow–residing progenitor cells like mesenchy-
mal stem cells, small embryonic-like cells, and endothelial 
progenitor cells.10 We here demonstrated that both short 
and long versions of this sphingolipid stimulated human 
ECFC migration. C1P not only increased per se the num-
ber of migrated ECFCs in a concentration-dependent 
manner (Figure 1C) but also potentiated chemotaxis 
driven by SDF-1—the most powerful chemoattractant 
factor for undifferentiated cells (Figure 1D).
C1P Enhances Other ECFC Responses Involved 
in Vasculogenesis
Based on the therapeutic potential of ECFC in regenera-
tive medicine, we next studied the effect of C1P in other 
responses, beyond chemotaxis, involved in vasculogene-
sis and tissue repair. To study ECFC adhesion, cells were 
placed onto a matrix protein-covered surface or cocul-
tured with endothelial cells for 1 hour in the presence 
or absence of C1P. Adhesion to collagen type I, but not 
fibronectin, significantly was augmented by 1 µmol/L C8- 
or 10 µmol/L C16-C1P (Figure 2A). Moreover, adhesion 
Figure 1. Ceramide 1-phosphate (C1P) promoted endothelial colony–forming cell (ECFC) survival and migration.  
A, ECFCs were treated with different concentrations of C8- or C16-C1P, and cell death was analyzed by fluorescence microscopy after 24 h 
(n=6–8). B, ECFCs were pretreated with C8- or C16-C1P for 30 min and then exposed to TNFα (tumor necrosis factor-α) and monosodium 
urate crystals (MSUs) at the indicated concentrations. Cell death was analyzed by fluorescence microscopy after 24 h (n=5–10). C-D) 
Chemotaxis in response to C8- or C16-C1P alone or together with SDF-1 (stromal cell-derived factor 1) was determined using transwell 
inserts. The number of migrated cells was counted after 6 h (n=4–6). *P<0.05 vs untreated controls; &P<0.05 vs TNFa or MSU alone; 
#P<0.05 vs SDF-1 alone, 1-way ANOVA.
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Figure 2. Ceramide 1-phosphate (C1P) enhanced endothelial colony–forming cell (ECFC) adhesion to collagen type I and 
endothelial cells.  
A and B, ECFCs were treated with C8- or C16-C1P and seeded onto collagen type I, fibronectin, untreated or TNFα (tumor necrosis 
factor-α)-activated human umbilical vein endothelial cell (HUVEC) for 1 h. The number of adherent cells was counted (n=4–7). C–F, 
ECFCs were treated with C8-C1P in the presence or absence of 2.5 mg/mL blocking antibodies against β1 integrin (αβ1), E-selectin 
(αCD62E), CD44 (αCD44), ICAM-1 (intercellular adhesion molecule 1; αCD54), or αIgG and seeded onto collagen type I or untreated 
HUVEC for 1 h. The number of adherent cells was counted (n=3–6). *P<0.05 vs untreated controls; #P<0.05 vs C8-C1P alone, 1-way 
ANOVA or Kruskal-Wallis.
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Figure 3. Ceramide 1-phosphate (C1P) increased endothelial colony–forming cell (ECFC) proliferation and tubulogenesis.  
A, ECFCs were cultured in endothelial basal medium 2 (EBM2)/2% fetal bovine serum (FBS) or endothelial growth medium 2 (EGM2) treated 
with C8- or C16-C1P at the indicated concentrations, and proliferation was analyzed by cell count in a Neubauer chamber after 24 and 48 h 
(n=4–5). The dashed line indicates the initial cell number seeded. B, ECFCs were cultured in EGM2 treated with C8-C1P in the presence or 
absence of 3 mg/mL blocking antibodies against VEGFR2 (vascular endothelial growth factor receptor 2) or αIgG, and (Continued )
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to mature endothelial cells (HUVECs) was increased by 
these sphingolipids in a concentration-dependent man-
ner, regardless of whether HUVECs were previously acti-
vated by TNFα or not (Figure 2B).
To understand the mechanism mediating the strong 
proadhesive action of C1P, we analyzed the participation 
of cell adhesion molecules like β1 integrin, coreceptor of 
collagen type I, as well as the E-selectin (CD62E)/CD44 
axis and ICAM-1 (intercellular adhesion molecule 1; 
CD54), possible mediators of ECFC-HUVEC interaction. 
Of note, the expression of these adhesion molecules was 
studied on each cell type before and after C1P treat-
ment, and only ICAM-1 was increased, whereas the rest 
of them remained unchanged (Figure I in the online-only 
Data Supplement). The enhanced adhesion to collagen 
type I was completely inhibited after β1 integrin block-
ade, whereas IgG control showed no effect (Figure 2C). 
Moreover, C8-C1P–induced adhesion to HUVEC was 
fully reduced in the presence of neutralizing antibodies 
against E-selectin or CD44, but not ICAM-1, indicat-
ing that the receptor/counterreceptor E-selectin-CD44 
binding is responsible for ECFC-HUVEC adhesion 
induced by C1P (Figure 2D through 2F). Furthermore, 
E-selectin mediates the interaction between the 2 endo-
thelial cell types after a 1-hour coculture without adding 
C1P or any activating factor. To investigate the kinetics of 
E-selectin expression in cocultures, we performed a time 
course assay in both ECFC and HUVEC grown alone or 
together. In ECFC, no significant changes were observed 
in E-selectin expression after 5 and 20 minutes of cocul-
ture, whereas a significant increment was detected after 
60 and 240 minutes of coculture. Similar data trends 
were observed in HUVECs, although an earlier signifi-
cant alteration tendency was detected in this cell type, 
after 20 minutes of coculture. In both cases, C1P further 
increased this process at early stages (20 and 6 minutes 
of coculture) but failed to potentiate E-selectin expres-
sion after 240 minutes (Figure II in the online-only Data 
Supplement).
Regarding cell proliferation, when ECFCs were cul-
tured in endothelial basal medium 2/2% fetal bovine 
serum, no cell growth was observed in any condition 
(with or without C1P) because the total cell number 
at 24 and 48 hours was similar to the amount initially 
seeded (≈10 000 cells; Figure 3A). As expected, ECFC 
growth was triggered by endothelial growth medium 
2—an effect that was potentiated by C8-C1P and C16-
C1P (1 and 10 µmol/L, respectively; Figure 3A). While 
C8-C1P slightly but significantly increased the total 
cell number after 24 hours, both C8- and C16-C1P 
augmented proliferation after 48 hours (Figure 3A). Flow 
cytometry analysis of cell division by carboxyfluorescein 
succinimidyl ester tracking yielded similar results after 24 
(untreated: 34±2, C8-C1P 0.1 µM: 29±1, C8-C1P 1 µM: 
46±3*, C16-C1P 1 µM: 33±1, C8-C1P 10 µM: 35±1% 
of positive cells; *P<0.05 versus untreated) and 48 hours 
(untreated: 49±1, C8-C1P 0.1 µM: 49±3, C8-C1P 1 µM: 
71±2*, C16-C1P 1 µM: 58±2, C8-C1P 10 µM: 66±3%* 
of positive cells; *P<0.05 versus untreated). The mito-
genic effect of C1P was completely suppressed in the 
presence of the neutralizing antibody against VEGFR2 
(vascular endothelial growth factor receptor 2), suggest-
ing that C1P-induced ECFC proliferation depends on 
VEGF (vascular endothelial growth factor)/VEGFR2 axis 
(Figure 3B). On the contrary, we observed that C8-C1P 
failed to modify the secretion of the proangiogenic fac-
tors VEGF and bFGF (basic fibroblast growth factor), 
as well as TGFβ1 (transforming growth factor-β1) and 
IL (interleukin)-4, whereas it significantly upregulated 
the release of the anti-inflammatory cytokine IL-10 and 
downregulated the release of the proinflammatory IL-8 
(Figure III in the online-only Data Supplement).
The formation of cord-like structures in vitro was 
significantly increased by C1P, C8-C1P being more 
potent than C16-C1P (Figure 3C). This effect was also 
observed in vivo using Geltrex plug implants in nude 
mice loaded (or not) with human ECFC. As shown in 
Figure 3D, C8-C1P not only has a potent vasculogenic 
effect by itself but also potentiates plug vascularization 
mediated by human ECFC.
ERK1/2 and AKT Pathways Are Involved in the 
Proangiogenic Effects of C1P
To elucidate the mechanism involved in the proangio-
genic effects of C8-C1P, we next studied some of the 
classical pathways involved in ECFC functions, which 
have been reported to be regulated by C1P in other cell 
types (eg, macrophages, cancer cells) such as ERK1/2, 
PI3K (phosphatidylinositol 3-kinase pathway)/AKT, P38, 
and NFκB. Flow cytometric analysis showed that C1P 
increased the percentage of positive cells for pERK1/2 
and pAKT but not for P38 and the NFκB subunit p65 
(Figure 4A). Activation of these pathways was confirmed 
by Western blot (Figure 4B). Furthermore, pERK1/2 and 
pAKT pathways are key mediators of C8-1P proangio-
genic effects since the increase in proliferation and che-
motaxis induced by C8-C1P was completely inhibited by 
the pharmacological inhibitors of ERK1/2 (U-0126) and 
AKT (LY-294002; Figure 4C).
Figure 3 Continued. proliferation was analyzed by cell count in a Neubauer chamber after 24 and 48 h (n=3–4). C, ECFCs were treated 
with C8- or C16-C1P at the indicated concentrations and then seeded on Geltrex matrix. The number of branch points per field was measured 
after 18 h. Images are representative of 6 different experiments. D, Geltrex plugs were loaded with C8-C1P, ECFC, or their combination 
and subcutaneously implanted in nude mice. After 10 d, implants were removed; the concentration of Hb (hemoglobin) was measured using 
the Drabkin reagent. Images are representative of 5 different experiments. *P<0.05 vs untreated controls; #P<0.05 vs same treatment in 
EBM2/2%FBS; &P<0.05 vs C8-C1P with IgG, 1-way or 2-way ANOVA, Fisher correction.
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Figure 4. Intracellular pathways involved in ceramide 1-phosphate (C1P) proangiogenic effects.  
A, Endothelial colony–forming cells (ECFCs) treated with C8-C1P for 10 min and the phosphorylation of ERK1/2 (extracellular signal-
regulated kinases 1 and 2), AKT, P38, and P65 were measured by flow cytometry (n=3–5). B, ECFCs treated with C8-C1P for 10 min and 
the phosphorylation of ERK1/2 and AKT was detected by immunoblotting. Each membrane was reprobed with an antibody against actin 
to calculate the relative IOD (n=4). C, ECFCs were treated with C8-C1P in the presence or absence of pharmacological inhibitors of AKT 
(LY-294002, 2.5 µmol/L) and ERK1/2 (U-0126, 2.5 µmol/L). Proliferation and C8-C1P–driven chemotaxis were determined after 48 and 6 h, 
respectively (n=3). *P<0.05 vs untreated controls; #P<0.05 vs C8-C1P alone, Student t test or 1-way ANOVA, Fisher correction.
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C1P Directly Promotes Tissue Revascularization 
Post-Ischemia and Enhances the Therapeutic 
Potential of ECFC
The effect of C1P on the ECFC therapeutic potential for 
tissue regeneration was studied in a murine model of 
hindlimb ischemia. As expected, the intravenous injec-
tion of untreated ECFC significantly augmented the 
ischemic-to-nonischemic leg blood flow ratio, relative to 
vehicle-treated mice (Figure 5). Intramuscular injections of 
C1P significantly enhanced the perfusion in the ischemic 
hindlimb in comparison with PBS and slightly increase 
the revascularization mediated by untreated ECFC alone 
(Figure 5). Interestingly, the best outcome was observed 
in animals that received both intravenous administration 
of C1P-pretreated ECFC together with intramuscular 
injection of C1P. This latter treatment resulted in further 
and significant improvement of leg reperfusion compared 
with each condition alone (Figure 5).
The histomorphometric analysis of the distal gastroc-
nemius muscles on day 14 was performed by dividing 
the digitized muscle sections into 3 areas: (1) preserved 
area: normal histology including homogeneous fibers and 
peripheral nuclei; (2) ischemic area: tissue in regeneration 
with cellular alterations and central nuclei; (3) necrotic area: 
muscle cell destruction, nonhomogeneous fibers, and mul-
ticellular infiltration (Figure 6A). Our results showed that 
animals receiving intramuscular injections of C1P alone sig-
nificantly reduced necrosis in the ischemic muscle in com-
parison with PBS-treated mice (Figure 6A), while capillary 
density was slightly increased (Figure 6B). As expected, 
intravenous infusion of untreated ECFC improved tissue 
repair significantly, although the administration of both 
untreated ECFC together with intramuscular injection of 
C1P showed no differences with animals receiving ECFC 
alone (Figure 6A and 6B). Outstandingly, administration of 
C1P-pretreated ECFC together with intramuscular C1P 
reduced necrosis and inflammatory infiltrate, exhibiting a 
higher percentage of preserved area (Figure 6A). Further-
more, this combined treatment resulted in a further and 
significant enhancement of capillary density compared 
with all conditions (Figure 6B). Of note, there was no epi-
sode of death or defects in ambulation in any group.
Considering that monocytes and macrophages are 
involved in vasculogenesis and C1P potently induced 
their migration, we aimed to analyze whether these 
immune cells play a role in the ECFC/C1P regenera-
tive effect. Few immune cells were observed after 7 and 
14 days post-surgery, showing no variances between the 
different experimental conditions (data not shown). An 
earlier analysis of muscle histology (day 4) showed that 
PBS-treated animals showed a considerable amount of 
macrophage infiltrating the ischemic muscles, which was 
higher when C1P alone was administered intramuscu-
larly. However, animals receiving ECFC alone or in com-
bination with C1P showed little macrophage infiltration 
(Figure IV in the online-only Data Supplement).
DISCUSSION
Therapeutic angiogenesis, and in particular, transplan-
tation of adult bone marrow cells, including ECFC, has 
Figure 5. Ceramide 1-phosphate (C1P) promotes postischemia tissue reperfusion.  
PBS, endothelial colony–forming cell (ECFC) alone, and C8-C1P–pretreated ECFC were infused intravenously 5 h after the ischemia-inducing 
surgery. C8-C1P was administrated intramuscularly (IM) 5 and 29 h after surgery. Perfusion index was calculated by Doppler analysis at day 
14. Representative Doppler images are shown (n=6–9). *P<0.05 vs PBS; #P<0.05 vs all other treatments, 1-way ANOVA.
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Figure 6. Administration of ceramide 1-phosphate (C1P)–pretreated endothelial colony–forming cell (ECFC) together with local 
C1P reduces necrosis and increased vascular density in the ischemic muscle.  
A, Histological analysis of gastrocnemius muscles, stained with hematoxylin and eosin, was performed at day 14. Representative images of preserved, 
ischemic, and necrotic areas in the gastrocnemius muscle post-ischemia are shown. Original magnification, ×40. Scale bar=200 µm. The surface of each 
area type is reported as a percentage of the entire histological section surface. B, Vessel density was calculated as the percentage of CD31+ vessels in 
the total surface. Representative images of immunohistochemistry are shown. Black arrows indicate CD31+ vessels. Original magnification, ×40. Scale 
bar=200 µm (n=4–9). *P<0.05 vs PBS; #P<0.05 vs C1P-pretreated ECFC+C1P (intramuscularly [IM]); &P<0.05 vs all the treatments, 1-way ANOVA.
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demonstrated exciting results and constitutes a prom-
ising approach for the treatment of ischemia.20 ECFC 
recruitment at the site of injury is a key step for tissue 
revascularization/repair, as well as their engraftment, 
which largely depends on the survival of the newly arrived 
cells within the hostile inflammatory microenvironment. In 
this sense, 2 of the best-known properties of C1P are 
chemoattraction and cytoprotection. Numerous studies 
support the antiapoptotic effect of C1P in different cell 
types. In macrophages and keratinocytes, higher levels 
of endogenous C1P (after CERK activity upregulation) 
blocked apoptosis,12,21 whereas the exogenous addition 
of C1P to cochlear hair cell and retina photoreceptor cul-
tures also increases cell survival.13,14 In line with this evi-
dence, we here demonstrated that C1P protects ECFC 
not only from apoptosis but also from necrosis triggered 
by 2 molecules highly elevated in the ischemic tissue like 
TNFα and monosodium urate crystal, respectively.18
We have used 2 analogs of C1P, a long-chain ana-
log (C16-C1P), which is a major type of C1P in cells, 
considered like the natural C1P,22 and a short chain one 
(C8-C1P), because of its higher solubility in water and 
cellular permeability than the long-chain C1P.23 In fact, 
Gangoiti et al24 previously showed that optimal DNA syn-
thesis was attained at lower concentrations when using 
C8-C1P than when using C16-C1P to stimulate cells. It 
is worth to mention that C8-C1P was not found in biolog-
ical systems; therefore, their effects should be observed, 
as others suggested,25 as only pharmacological. Regard-
ing cytoprotection, we found that C8-C1P exerted it 
maximal protective effect at 1 µmol/L and higher con-
centrations induced ECFC apoptosis, whereas C16-C1P 
failed to induce ECFC death in all concentrations tested 
(0.1–10 µmol/L) and effectively reduced cell death at 
10 µmol/L. Both C1P analogs showed similar effects on 
ECFC functions when used at the maximum noncyto-
toxic concentration.
As mentioned above, C1P is a well-known chemoat-
tractant factor of monocytes, macrophages,15,26 pancre-
atic cancer cells,27 mesenchymal stem cells,28 endothelial 
cells,29 and several murine precursors, including bone 
marrow–derived endothelial progenitor cells.9,10 Our data 
showed that C1P acted as a potent chemoattractant 
factor for human ECFC and additionally potentiated the 
chemotactic effect of SDF-1—the major ECFC physi-
ological chemotactic factor. Because it has been shown 
that C1P levels are upregulated in damaged tissues like 
carotid injury,30 irradiation,9,10 ischemic myocardium,10,31 
our findings suggest that C1P, like SDF-1, can create a 
gradient to attract ECFC to the injury site.
The angiogenic process involves ECFC homing and 
adhesion to activated endothelium or matrix proteins and 
their extravasation to target sites. In vivo, endothelial pro-
genitor cells usually home to areas of altered shear stress, 
where the endothelial monolayer is activated and possi-
bly denuded, exposing extracellular matrix proteins to the 
vascular lumen.32 These areas are believed to influence 
the adhesion and extravasation of progenitor cells to isch-
emic sites. Our results provide strong evidence that C1P 
stimulation enhances these events by promoting ECFC 
adhesion to collagen type I and mature endothelial cells 
(HUVEC). In this regard, β1 integrin seems to be respon-
sible for C1P-induced ECFC adhesion to collagen as the 
effect was completely suppressed after its blockade. In 
addition, a complete inhibition of C1P-triggered adhesion 
to HUVEC was observed in the presence of neutralizing 
antibodies against E-selectin or CD44, but not ICAM-1, 
indicating that the E-selectin/CD44 axis is responsible 
for ECFC-HUVEC adhesion induced by C1P. Moreover, 
we observed that E-selectin also mediates the interaction 
between the 2 endothelial cell types after a 1-hour cocul-
ture without adding any activating factor, reinforcing the 
idea that coculturing itself promotes E-selectin expres-
sion and further suggesting that C1P-independent endo-
thelial cell interaction is also mediated by E-selectin and 
CD44. These results raised the question: is it possible 
that E-selectin is significantly expressed on endothelial 
surface after 1-hour stimulation with C1P? Our results 
indicated that indeed, E-selectin is rapidly induced on 
each cell type when cultured together in the presence of 
C1P—a phenomenon that it is not observed when ECFC 
and HUVEC are grown separately. To the best of our 
knowledge, we here report that E-selectin is significantly 
expressed on ECFC surface as early as 60 minutes after 
coculture with HUVEC. Similar data were observed in 
HUVEC, although an earlier significant alteration ten-
dency was detected in these cells, after 20 minutes of 
coculture. A fast expression of E-selectin on HUVEC 
has been reported before when cultured together with 
smooth muscle cells,33 after 15-minute stimulation with 
nicotine34 or 30-minute post-Flavivirus infection.35 More-
over, E-selectin expression was observed as early as 30 
minutes after lipopolysaccharide administration in an in 
vivo model of cutaneous inflammation.36 The mechanisms 
of C1P-mediated E-selectin upregulation have not been 
investigated here. However, considering that the sole 
interaction between cells triggers E-selectin expression 
and C1P effect is only observed when cells are cultured 
together, it is conceivable that C1P acts as an enhancer 
of the cross talk between them.
It has been previously reported that C1P increased 
HUVEC adhesion to plastic, although the mechanisms 
involved were not identified.10 Additionally, C1P increased 
the expression of ICAM-1 on ECFC surface, although 
its blockade has no effect on ECFC-HUVEC interac-
tion. Considering that C1P participates and regulates the 
inflammatory response,37 it is conceivable that ICAM-1 
mediates ECFC contact with leukocytes—a fundamen-
tal step to allow the migration of these cells to the site 
of injury. Moreover, our results showing that C1P failed 
to modify the secretion of proangiogenic factors (VEGF, 
bFGF, etc) while significantly upregulated the release of 
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the anti-inflammatory cytokine IL-10 and downregulated 
the release of the proinflammatory IL-8 strengthen the 
idea that C1P regulates ECFC inflammatory responses. 
Similarly, it has been previously reported that C1P sup-
presses the release of proinflammatory cytokine from 
macrophages.38–40 How C1P regulates inflammation and 
the consequences for tissue repair is an interesting area 
of future investigation.
Other ECFC responses involved in vasculogenesis 
were also augmented by C1P. Although C1P had no 
effect itself on cell proliferation, both C8-C1P and C16-
C1P induced ECFC expansion in the presence of a mod-
erate amount of growth factors (1:2 dilution endothelial 
growth medium 2), suggesting a collaborative effect 
between them and C1P. In addition, this mitogenic action 
of C1P was completely suppressed by VEGFR2 block-
ade. In line with our finding, the involvement of VEGF/
VEGFR2 axis on C1P-induced proliferation has been 
reported in RAW264.7 macrophages,41 C8-C1P aug-
mented ECFC proliferation over time, whereas C16-C1P 
only showed significant differences after 48 hours. A sim-
ilar C8-C1P–mediated mitogenic effect was previously 
observed in macrophages42 and aortic vascular smooth 
cells30 but not in C16-C1P–stimulated MSCs and mature 
endothelial cells (HUVEC, HREC, and HCAEC).9,10,29 The 
lack of effect of C16-C1P was probably because pro-
liferation was analyzed after 24-hour stimulation—a time 
point in which we also failed to detect any effects. We 
also demonstrated that C1P promoted the formation of 
capillary-like network mediated by ECFC in vitro and the 
vasculogenesis in vivo in a murine model of subcutaneous 
implants of ECFC-loaded gel plugs. In addition, a proan-
giogenic effect of C1P per se was observed in this model. 
In agreement with our findings, Kim et al10 showed that a 
long-chain analog of C1P, C18-C1P, increased HUVEC-
mediated angiogenesis in vitro and in gel plug implants. 
Moreover, CERK−/− murine microvascular endothelial 
cells showed an impaired tubule formation capacity.16
The classical intracellular signaling pathways activated 
by C1P include PI3K/AKT, MAPK ERK1/2, MAPK P38, 
and NFκB, which are responsible for the chemotactic 
effect of this sphingolipid in macrophages and pancre-
atic cancer cells.15,26,27 In line with this evidence, we here 
showed that C1P triggers phosphorylation of PI3K/AKT 
and MAPK ERK1/2, although P38 or NFκB were not 
affected. Likewise, both C1P-enhaced proliferation and 
chemotaxis were fully abrogated by pharmacological 
inhibitors of AKT and ERK1/2, suggesting these path-
ways as crucial molecular mechanisms mediating C1P 
proangiogenic action on ECFC.
The relevance of these in vitro findings was con-
firmed using an in vivo murine model of hindlimb isch-
emia. Animals receiving intramuscular injections of C1P 
significantly increased recovery of blood perfusion and 
reduced necrosis in the ischemic muscle in compari-
son with PBS-treated mice, while capillary density was 
slightly increased. The C1P-mediated tissue protection 
might be associated with its anti-inflammatory43 and 
cytoprotective properties,11–14 although more studies are 
required to elucidate this issue. Despite our in vitro data 
showing that C1P strongly chemoattracts ECFC, intra-
venous administration of untreated ECFC together with 
intramuscular injection of C1P showed no differences 
with animals receiving ECFC alone. It is conceivable that 
the elevated endogenous C1P levels at the ischemic 
tissue,10,31 along with other chemokines, are enough to 
achieve the maximum possible chemoattractant effect 
and the exogenous addition of this sphingolipid failed 
to produce a greater ECFC attraction. Interestingly, the 
beneficial effects of ECFC infusion were amplified sig-
nificantly by C1P pretreatment of these progenitor cells. 
Pretreated ECFC together with an intramuscular C1P 
injection improved their therapeutic outcome, resulting in 
a further and significant enhancement of leg reperfusion, 
a tissue necrosis reduction, and a capillary density incre-
ment. The angiogenic potency of the C1P-stimulated 
ECFC is likely to be attributable to both the beneficial 
effects of C1P on the proangiogenic potential of trans-
planted ECFC and the influence of C1P and ECFC on 
the ischemic hindlimb. In line with our evidence, it has 
been demonstrated that the priming of MSC with C1P 
improved the regenerative effect of these cells in a pul-
monary artery hypertension rat model.28
Considering that C1P is a well-known chemoattractant 
factor for monocytes and macrophages, we would expect 
a higher number of monocytes/macrophages present 
within the ischemic muscles of animals treated with C1P 
alone and in combination with ECFC. While this is true for 
C1P alone, few inflammatory infiltrates were observed in 
ECFC-treated animals. Although these findings suggest 
that the number of macrophages/monocytes within the 
damaged area is not crucial for ECFC/C1P-mediated 
tissue repair, we cannot rule out that these immune cells 
still participate in this process at different time points or 
under other experimental conditions. In addition, the type 
of monocytes and macrophages migrating from periph-
eral blood or their polarization into inflammatory or anti-
inflammatory phenotype among the different treatments 
should be considered as well. These issues are currently 
under investigation in our laboratory.
In conclusion, our finding suggests that C1P may be 
considered a new therapeutic tool in ischemic disorders, 
promoting tissue repair by itself or as a primer of ECFC 
survival and angiogenic responses, which result in a bet-
ter outcome of ECFC-based therapy.
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